In this study, through screening known USPs inhibitors against USP22 DUB complex, we, for the first time, surprisedly found that pharmaceutical inhibition or knockdown of USP7 can dramatically upregulate USP22 protein in cancer cells independent of these cells’ p53 status. This evidence concerns the gene TP53 and cancer.